Bone-targeted therapies in metastatic castration-resistant prostate cancer
Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , |
| Format: | article |
| Published: |
2013
|
| Online Access: | http://hdl.handle.net/10725/6241 http://dx.doi.org/10.1155/2013/210686 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.hindawi.com/journals/pc/2013/210686/abs/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!